Skip to content
Clinical Trials – home
Not recruiting

Bioavailability of esomeprazole magnesium trihydrate oral solution 40 mg compared with gastro‑resistant tablets in healthy volunteers under fasting and fed conditions

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Esomeprazole is a medication commonly used to reduce stomach acid and treat conditions such as heartburn, gastroesophageal reflux disease, and ulcers. In this study the drug is given either as a liquid form called Esomeprazole‑Syrup 40 mg or as a tablet marketed under the name Nexium 40 mg.

The purpose of the study is to compare the bioavailability of the liquid formulation with that of the tablet, meaning how much of the medicine reaches the bloodstream after a single dose. The researchers will measure the total exposure of the drug in the blood, known as AUC, and the highest level reached, called Cmax, as well as the time it takes to reach that highest level.

Healthy volunteers will take one dose of the liquid and one dose of the tablet on separate visits, with each visit performed after an overnight fast and after a standard meal, creating four different testing periods. The visits are spaced several days apart, and blood samples are collected after each dose to determine how the body absorbs the medication under the different conditions.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    First Study Visit – Fasting with Test Syrup

    On the day of the first visit you will fast for at least 10 hours, meaning no food or drink except water.

    After confirming the fasting state you will take a single oral dose of 40 mg esomeprazole provided as an oral solution (syrup) in a 10 mL volume.

    No further medication is taken during this period, and you will remain in the clinic for a short observation.

    A washout period of at least 7 days must pass before the next dose.

  2. Step 2

    Second Study Visit – Fed with Test Syrup

    At least 7 days after the first visit you will return for the second visit.

    You will eat a standardized high‑fat breakfast, creating the fed condition.

    Within 30 minutes after finishing the meal you will take a single dose of 40 mg esomeprazole as the same oral solution (syrup).

    No additional medication is taken, and you will stay for observation.

    Another washout period of at least 7 days is required before the third visit.

  3. Step 3

    Third Study Visit – Fasting with Comparator Tablet

    After a further washout period of at least 7 days you will attend the third visit under fasting conditions.

    You will fast for at least 10 hours before arriving.

    You will swallow one gastro‑resistant tablet containing 40 mg esomeprazole. The tablet is designed to resist stomach acid until it reaches the intestine.

    No other medication is taken, and you will be observed for a short time.

    A final washout period of at least 7 days separates this visit from the last one.

  4. Step 4

    Fourth Study Visit – Fed with Comparator Tablet

    The final visit occurs after the last washout period of at least 7 days.

    You will eat the same standardized meal as in the fed condition.

    Within 30 minutes after the meal you will take one 40 mg esomeprazole gastro‑resistant tablet.

    No further medication is taken, and after a short observation period the trial is complete.

Who can join the trial?

8 criteria

  • Be a male or female volunteer.
  • Be between 18 and 55 years old on the day you sign the consent form.
  • If you are a female who cannot become pregnant, you must meet one of these conditions: have naturally stopped having periods for at least 12 months (natural menopause), have had both ovaries removed at least 6 weeks ago (bilateral oophorectomy), or have had a permanent tubal blockage procedure (bilateral tubal ligation). Periods that stopped because of an illness do not count.
  • If you are a female who could become pregnant, you must use a reliable birth‑control method (or be willing to start one) at least 4 weeks before the screening visit and continue it for the whole study. Accepted methods include: a barrier method (like condoms) used together with sperm‑killing chemicals (spermicides); hormonal methods such as birth‑control pills, injections, patches, rings, or implants; and intrauterine devices (IUDs), either copper or hormonal.
  • Be physically and mentally healthy, as shown by a medical check‑up and standard lab tests.
  • Be a non‑smoker or a former smoker who quit at least 6 months ago, with a smoking history of no more than 5 pack‑year equivalents (one pack per day for one year). You also must not use any other nicotine products, and a urine test for nicotine (cotinine) must be negative.
  • Have a body‑mass index (BMI) between 18.5 and 30.0 kg/m², which is a measure of weight relative to height.
  • Provide written informed consent to take part in the study.

Who cannot join the trial?

30 criteria

  • You cannot take part if you are already enrolled in another clinical trial or have been in one within the past 90 days.
  • People with a strong tendency to develop allergies (called allergic diathesis) or any serious allergic condition such as asthma or overly reactive airways are excluded.
  • If you have ever had a serious allergic reaction to the ingredients in esomeprazole medicines (for example fructose, sorbitol, or methylparaben), you cannot join.
  • Anyone who currently has or has had major diseases of the heart, kidneys, liver, lungs, metabolism, hormones, blood, digestive system, nerves, mind, or other important body systems is not eligible.
  • A serious illness that occurred within four weeks before the screening visit will disqualify you.
  • Having had major surgery on the digestive tract (except a simple appendix removal) will exclude you.
  • If you have a long‑lasting disease that could change how the drug is absorbed, spread, broken down, or removed from your body, you cannot participate.
  • People who have difficulty swallowing are not allowed to join.
  • A positive test for HIV antibodies, hepatitis B surface antigen, or hepatitis C antibodies will make you ineligible.
  • Receiving long‑acting injectable medicines (called depot injections) or any drug that stays in the body for more than one week (half‑life > 1 week) within the past six months excludes you.
  • Taking medicines that increase enzyme activity, damage organs, or have a long half‑life within four weeks before screening will disqualify you.
  • If you have already been randomly assigned to this trial more than once, you cannot join again.
  • Using any prescription or over‑the‑counter medication (including antacids like aluminum hydroxide, magnesium hydroxide, simethicone, or herbal products such as St John’s wort or kava) within two weeks before screening makes you ineligible.
  • Having received any vaccination within the 14 days before the screening visit will exclude you.
  • Taking drugs that affect major organs (for example barbiturates, phenothiazines, cimetidine, or omeprazole) within the past 60 days will disqualify you.
  • If your resting blood pressure is lower than 100 mmHg or higher than 140 mmHg (systolic) or your diastolic pressure is outside 60‑90 mmHg, you cannot participate.
  • A resting pulse rate below 50 beats per minute or above 90 beats per minute will exclude you.
  • Your body temperature must be between 35.5 °C and 37.1 °C; otherwise you are not eligible.
  • Any significant abnormal finding on a resting heart tracing (ECG) will disqualify you.
  • Laboratory test results that are outside the normal range and considered clinically important will exclude you.
  • Following a special diet for any reason (for example being vegetarian) makes you ineligible.
  • Having mouth piercings, wearing braces, or using dentures will exclude you.
  • Donating blood or losing more than 500 mL of blood (including plasmapheresis) within the past 90 days will disqualify you.
  • People who are unlikely to follow the study rules, cannot understand the information, are in legal custody, or are in a very unstable financial situation are excluded.
  • A history of drug abuse, such as using marijuana within the past six months or using hard drugs (e.g., cocaine, amphetamines, PCP) within the past year, will exclude you.
  • Alcohol abuse, defined as drinking more than two standard drinks per day or ten drinks per week, having a history of alcoholism, or being a recovered alcoholic, makes you ineligible.
  • Regular consumption of coffee, tea, cola, chocolate, or other foods and drinks containing caffeine (methylxanthines) that adds up to more than 500 mg per day will exclude you.
  • A positive result on a drug screening test will disqualify you.
  • A positive result on an alcohol test will exclude you.
  • Pregnant or nursing women, or anyone with a positive pregnancy test, cannot take part in the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Esomeprazole syrup

    is a liquid medicine taken by mouth that contains esomeprazole, a drug that lowers the amount of acid your stomach makes. In this study it is the new test product, and researchers are checking how well the body absorbs it when taken on an empty stomach and after a meal.

  • Nexium tablets

    are the standard, market‑available pills that also contain esomeprazole. They have a special coating that protects the medicine from stomach acid until it reaches the intestine. In the trial they are used as the comparison product to see if the syrup works as well as these well‑known tablets.

What is already known about the treatment

  • ESO SY 40

    This product is an oral solution (syrup) that delivers 40 mg of esomeprazole magnesium trihydrate in 10 mL and is taken by mouth. It contains a drug that is already approved and well‑studied in medical literature as a proton‑pump inhibitor. It is used to treat conditions caused by excess stomach acid, such as heartburn, gastro‑esophageal reflux disease, and ulcers. It works by blocking the stomach’s acid‑producing pump (the H⁺/K⁺‑ATPase), which lowers the amount of acid released, and it belongs to the class of proton‑pump inhibitors.

  • Nexium mups 40 mg magensaftresistente Tabletten

    This product is a gastro‑resistant tablet that contains 40 mg of esomeprazole magnesium trihydrate and is swallowed whole. It is an approved medication with extensive documentation in the medical literature as a proton‑pump inhibitor. It is indicated for the same acid‑related conditions such as heartburn, gastro‑esophageal reflux disease, and ulcer disease. It reduces stomach acid by inhibiting the H⁺/K⁺‑ATPase pump in the stomach lining and is classified as a proton‑pump inhibitor.

Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-506701-18-00Protocol codeCBP23001Estimated enrolment18 patientsSponsorBePharBel Manufacturing

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.